



## POLICY STATEMENT

## Contraception for Adolescents

## abstract

FREE

Contraception is a pillar in reducing adolescent pregnancy rates. The American Academy of Pediatrics recommends that pediatricians develop a working knowledge of contraception to help adolescents reduce risks of and negative health consequences related to unintended pregnancy. Over the past 10 years, a number of new contraceptive methods have become available to adolescents, newer guidance has been issued on existing contraceptive methods, and the evidence base for contraception for special populations (adolescents who have disabilities, are obese, are recipients of solid organ transplants, or are HIV infected) has expanded. The Academy has addressed contraception since 1980, and this policy statement updates the 2007 statement on contraception and adolescents. It provides the pediatrician with a description and rationale for best practices in counseling and prescribing contraception for adolescents. It is supported by an accompanying technical report. *Pediatrics* 2014;134:e1244–e1256

## INTRODUCTION

Pediatricians play an important role in adolescent pregnancy prevention and contraception. Nearly half of US high school students report ever having had sexual intercourse.<sup>1</sup> Each year, approximately 750 000 adolescents become pregnant, with more than 80% of these pregnancies unplanned, indicating an unmet need for effective contraception in this population.<sup>2,3</sup> Although condoms are the most frequently used form of contraception (52% of females reported condom use at last sex), use of more effective hormonal methods, including combined oral contraceptives (COCs) and other hormonal methods, was lower, at 31% and 12%, respectively, in 2011.<sup>1</sup> Use of highly effective long-acting reversible contraceptives, such as implants or intrauterine devices (IUDs), was much lower.<sup>1</sup>

Adolescents consider pediatricians and other health care providers a highly trusted source of sexual health information.<sup>4,5</sup> Pediatricians' long-term relationships with adolescents and families allow them to ask about sensitive topics, such as sexuality and relationships, and to promote healthy sexual decision-making, including abstinence and contraceptive use for teenagers who are sexually active. Additionally, medical indications for hormonal contraception, such as dysmenorrhea, heavy menstrual bleeding or other abnormal uterine bleeding, acne, and polycystic ovary syndrome, are often uncovered during adolescent visits. A working knowledge of contraception will assist the pediatrician in both sexual health promotion and treatment of common

## COMMITTEE ON ADOLESCENCE

## KEY WORDS

contraception, adolescent, birth control, intrauterine device, contraceptive implant, oral contraceptive pills, contraceptive injection

## ABBREVIATIONS

AAP—American Academy of Pediatrics  
ACOG—American College of Obstetricians and Gynecologists  
BMD—bone mineral density  
CDC—Centers for Disease Control and Prevention  
COC—combined oral contraceptive  
DMPA—depot medroxyprogesterone acetate  
EC—emergency contraception  
FDA—Food and Drug Administration  
HIPAA—Health Insurance Portability and Accountability Act  
IUD—intrauterine device  
LARC—long-acting reversible contraception  
PID—pelvic inflammatory disease  
STI—sexually transmitted infection

This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

The guidance in this statement does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

All policy statements from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

[www.pediatrics.org/cgi/doi/10.1542/peds.2014-2299](http://www.pediatrics.org/cgi/doi/10.1542/peds.2014-2299)

doi:10.1542/peds.2014-2299

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2014 by the American Academy of Pediatrics

adolescent gynecologic problems. Contraception has been inconsistently covered as part of insurance plans. However, the Institute of Medicine has recommended contraception as an essential component of adolescent preventive care,<sup>6</sup> and the Patient Protection and Affordable Care Act of 2010 (Pub L No. 111–148) requires coverage of preventive services for women, which includes contraception, without a copay.<sup>7,8</sup>

## SETTING THE STAGE

### Confidentiality and Consent

In the setting of contraception and sexual health care, the American Academy of Pediatrics (AAP) believes that policies supporting adolescent consent and protecting adolescent confidentiality are in the best interests of adolescents. Accordingly, best practice guidelines recommend confidentiality around sexuality and sexually transmitted infections (STIs) and minor consent for contraception.<sup>9–11</sup> The majority of states have specific laws regarding minor consent to contraception (see *State Minor Consent Laws: A Summary*<sup>12</sup> and the Guttmacher Institute's State Center<sup>13</sup> at <http://www.guttmacher.org/statecenter/> for regularly updated state-by-state summaries). For states without specific laws, best practice guidelines, federal statutes, and federal case law may support minor confidentiality and consent.<sup>12</sup> For example, family planning clinics funded by Title X of the federal Public Health Services Act (42 USC §§300–300a-6 [1970]) are required to provide confidential services to adolescents.<sup>12</sup>

The Health Insurance Portability and Accountability Act (HIPAA [Pub L No. 104–191, 1996]) specifically addresses minor confidentiality. Although HIPAA allows parents access to a minor's records as personal representatives, that access is denied when the minor is provided with confidentiality under state or other laws or when the parent agrees that the minor may have confidential

care.<sup>14</sup> Therefore, the AAP recommends that pediatricians have an office policy that explicitly describes confidential services and that pediatricians discuss (and document) confidentiality with all parents and adolescents. As an additional protection for minors' confidentiality, HIPAA states that if there is no applicable state law about the rights of parents to access the protected health information of their children, pediatricians (or other licensed health professionals) may exercise their professional judgment to provide or deny parental access to the records.<sup>14</sup> This can be accomplished with careful documentation of their professional judgment. Insurance, billing, and electronic health record systems create additional challenges, including maintaining the confidentiality of visits, visit content, associated laboratory test results, and payment for the contraceptive method itself.<sup>15</sup> For additional discussion of electronic health records, see the AAP policy statement on health information technology.<sup>16</sup>

Careful attention to minor consent and confidentiality is important, because limitations on confidentiality and consent are linked to lower use of contraceptives and higher adolescent pregnancy rates.<sup>17–21</sup> Parents need not be adversaries; in fact, many parents are supportive of minor consent and confidentiality for sexual health services.<sup>22,23</sup> As permitted by law, adolescent contraception should be provided as a confidential service, with adolescents encouraged to involve parents or trusted adults as they are able.

### Sexual History Taking and Counseling

Bright Futures recommends that pediatricians take a developmentally targeted sexual history, assess STI and pregnancy risk, and provide appropriate screening, counseling, and, if needed, contraceptives.<sup>24</sup> Key to history taking is an

honest, caring, nonjudgmental attitude and a comfortable, matter-of-fact approach to asking questions. This can be accomplished by assessing the 5 Ps of sexual history taking, as described by the Centers for Disease Control and Prevention (CDC): partners, prevention of pregnancy, protection from STIs, sexual practices, and past history of STIs and pregnancy.<sup>25</sup> Counseling should draw on motivational interviewing approaches, with the focus of the interview on future goals, belief in the adolescents' capacity to change, and engagement of the adolescent in the process of adopting health-promoting behaviors.<sup>26</sup> For an example of motivational interviewing for sexual health counseling, see Ott et al (2007),<sup>27</sup> and for a more detailed discussion of counseling approaches, see the accompanying technical report.<sup>28</sup>

### Counseling About Abstinence and Contraception

Counseling about abstinence and postponement of sexual intercourse is an important aspect of adolescent sexual health care. Abstinence is 100% effective in preventing pregnancy and STIs and is an important part of contraceptive counseling. Adolescents should be encouraged to delay sexual onset until they are ready. However, existing data suggest that, over time, perfect adherence to abstinence is low (ie, many adolescents planning on abstinence do not remain abstinent).<sup>29,30</sup> Therefore, pediatricians should not rely on abstinence counseling alone but should additionally provide access to comprehensive sexual health information to all adolescents. For sexually active adolescents, including gay and lesbian adolescents,<sup>31</sup> and those considering initiation of sexual activity, counseling additionally includes initiating contraception, supporting adherence to the contraceptive method, managing adverse effects, and providing periodic screening for STIs.<sup>24</sup>

## METHODS OF CONTRACEPTION

This section summarizes the contraceptive options for adolescents; the accompanying technical report provides more detailed information on each of the methods. When comparing the efficacy of different methods, it is important to distinguish between typical use and perfect use, and counseling should be based on typical use. Typical use efficacy refers to the probability of pregnancy during the first year of typical use and includes users with varying degrees of adherence; perfect use efficacy is the probability of pregnancy if used consistently and correctly every time.<sup>32</sup> The most effective methods rely the least on individual adherence; for these methods, typical use effectiveness approaches perfect use effectiveness. Contraceptive methods most commonly used by adolescents are listed below, ordered from most to least effective, starting with long-acting reversible contraception (LARC): implants and IUDs. *Pediatricians are encouraged to counsel adolescents in that order, discussing the most effective contraceptive methods first* (see Table 1 for contraceptive effectiveness).

### Progestin Implants

Implanon and Nexplanon (Merck, Whitehouse Station, NJ) are both single-rod implants that contain etonogestrel, the active metabolite of the progestin desogestrel. Implants, a LARC method, are highly effective, with typical and perfect use failure rates of less than 1%<sup>32,35</sup>; they may remain in place for 3 years. The implant is inserted into the inside of the upper arm by a clinician who has completed the requisite training. Implants are ideal for adolescents who prefer a method that does not require regularly scheduled adherence and who desire an extended length of protection. A common reason for discontinuation is unpredictable bleeding or spotting.<sup>34,35</sup>

**TABLE 1** Contraceptive Method Efficacy

Method	% of Women Experiencing an Unintended Pregnancy in the First Year of Use		% of Women Continuing Use at 1 Year <sup>a</sup>
	Typical Use <sup>b</sup>	Perfect Use <sup>c</sup>	
No method	85	85	—
Spermicides (foams, creams, gels, suppositories, and film)	28	18	42
Fertility awareness–based methods	24	—	47
Withdrawal	22	4	46
Condom			
Female	21	5	41
Male	18	2	43
Diaphragm	12	6	57
Combined pill and progestin-only pill	9	0.3	67
Contraceptive patch	9	0.3	67
Contraceptive ring	9	0.3	67
DMPA contraceptive injection	6	0.2	56
IUD			
Copper T	0.8	0.6	78
Levonorgestrel	0.2	0.2	80
Single-rod contraceptive implant	0.05	0.05	84
Female sterilization	0.5	0.5	100
Male sterilization	0.15	0.10	100

—, data not available.

<sup>a</sup> Among couples attempting to avoid pregnancy, the percentage who continue to use a method for 1 y.

<sup>b</sup> Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. Estimates of the probability of pregnancy during the first year of typical use for spermicides, withdrawal, periodic abstinence, the diaphragm, the male condom, the pill, and Depo-Provera are taken from the 1995 and 2002 National Survey of Family Growth, corrected for underreporting of abortion; see the text for the derivation of estimates for the other methods.

<sup>c</sup> Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.

Contraceptive implants can also be offered to pregnant adolescents and provided in the immediate postpartum period, while the adolescent is still in the hospital. The American College of Obstetricians and Gynecologists (ACOG) and the CDC both support immediate postpartum insertion of implants as a safe and effective practice that removes barriers to care.<sup>36,37</sup> The main theoretical concern about contraceptive implant use in the postpartum period is whether the progestin might have some effect on breastfeeding; however, studies of contraceptive implant use among breastfeeding women have generally found no effects on breastfeeding performance or infant health and growth.<sup>38,39</sup> When starting an implant, patients should be counseled that a backup method (ie, condoms or abstinence) should be used for at least

the first week for contraceptive efficacy and that a condom should be used at all times for protection against STIs.

### IUDs

IUDs inserted into the uterus also provide long-acting reversible contraception. Three IUDs currently are approved in the United States: 2 levonorgestrel-releasing T-shaped IUDs (Mirena, 52 mg levonorgestrel, and Skyla, 13.5 mg levonorgestrel; Bayer HealthCare Pharmaceuticals Inc, Wayne, NJ) and a copper-containing T-shaped IUD (Copper T380-A, ParaGard; Teva North America, North Wales, PA). The 13.5-mg levonorgestrel IUD is approved for 3 years,<sup>40</sup> the 52-mg levonorgestrel IUD is approved for 5 years,<sup>41</sup> and the copper IUD is approved for 10 years.<sup>42</sup> Despite their low but increasing use in the United

States, IUDs are used extensively worldwide because they are safe and effective methods of contraception with typical and perfect use failure rates of less than 1%.<sup>43</sup> The copper IUD can be used as emergency contraception (EC) within 5 days of unprotected intercourse.<sup>43,44</sup>

Despite past concerns, IUDs are now known to be safe for nulliparous adolescents. IUDs themselves do not cause tubal infertility in nulliparous women,<sup>45</sup> and studies support a rapid return to fertility after IUD removal.<sup>46,47</sup> The risk of pelvic infection with IUDs occurs only during insertion. Beyond the first 21 days, IUDs do not increase rates of STIs or pelvic inflammatory disease (PID).<sup>48,49</sup> Unless the adolescent is at very high risk for STIs (eg, had sex with a partner with known gonorrhea), screening for gonorrhea and chlamydia can be performed on the day of insertion.<sup>50</sup> Treatment, if needed, can be subsequently provided without IUD removal, because studies have demonstrated that, provided the patient improves with treatment, both STIs and PID can be treated with the IUD in place.<sup>51,52</sup> Contraindications to IUD placement are limited to current purulent cervicitis, gonorrhea, or chlamydia, current PID and other current pelvic infections (see "US Medical Eligibility Criteria for Contraceptive Use" for more extensive discussion).<sup>37</sup> Past PID is not a contraindication to IUD use. HIV infection and immunosuppression are also not contraindications to IUD use.

IUDs can also be offered to pregnant adolescents and provided in the immediate postpartum period, while the adolescent is still in the hospital. Two systematic reviews concluded that immediate postpartum insertion of IUDs is safe and effective,<sup>53,54</sup> and both ACOG and the CDC support this practice.<sup>36,37,55</sup> Studies have shown that many women who desire an IUD at the time of delivery do not return for later insertion and

that immediate insertion of IUDs provides similar contraceptive coverage as delayed insertion, even with higher expulsion rates with immediate insertion.<sup>56,57</sup>

The emerging adolescent-specific data on IUDs are promising. However, there are some disadvantages. The limited data in adolescents suggest that expulsion, which occurs in fewer than 5% of women using IUDs, may occur more frequently in younger women.<sup>58</sup> Another concern is that more than half of young nulliparous women report moderate to severe pain with insertion.<sup>59,60</sup> Nonetheless, studies demonstrate IUD continuation rates in adolescents that exceed those with other hormonal methods and effective use of the levonorgestrel IUD for menstrual suppression in adolescent patients with complex medical conditions.<sup>61–67</sup>

### Progestin-Only Injectable Contraception

Depot medroxyprogesterone acetate (DMPA, also known by the brand name Depo-Provera; Pfizer, New York, NY) is a long-acting progestin that is given as a single injection every 13 weeks (up to 15 weeks) using a dose of either 150 mg delivered intramuscularly or 104 mg delivered subcutaneously. Many health care providers schedule visits every 11 to 12 weeks for adolescents to allow for missed or delayed visits. Both regimens have similar effectiveness and side effects<sup>68</sup> and are highly effective in preventing pregnancy. In the first year of use, the probability of becoming pregnant with typical use is approximately 6%.<sup>52</sup> DMPA can be initiated on the same day as the visit ("mid-cycle" or "quick" start) as long as the health care provider is reasonably certain the adolescent is not pregnant. For additional details, see the accompanying technical report and the CDC's 2013 "US Selected Practice Recommendations for Contraceptive

Use."<sup>52</sup> When starting DMPA, patients should be counseled that a backup method (eg, condoms or abstinence) should be used for at least the first week for contraceptive efficacy and that a condom should be used at all times for protection against STIs.

DMPA is convenient for many adolescents because of its ease of use. Other advantages include improvement in dysmenorrhea and protection against iron deficiency anemia and endometrial cancer.<sup>69</sup> DMPA is safe for most patients with chronic illness,<sup>37</sup> is thought to raise the seizure threshold in adolescents with epilepsy,<sup>70</sup> and may decrease sickle cell crises.<sup>71,72</sup>

The major disadvantages of DMPA include the need for an injection every 13 weeks and the menstrual cycle irregularities that are present for nearly all patients initially. These menstrual irregularities typically improve over time<sup>73,74</sup> and may be less likely to result in discontinuation if patients are counseled about these effects before the first injection.<sup>75,76</sup> Other possible adverse effects include headache, mastalgia, hair loss, change in libido, and weight gain. Studies in both adolescents<sup>77</sup> and adults<sup>78</sup> suggest that weight gain status at 6 months is a strong predictor of future excessive weight gain with ongoing DMPA use, but that weight gain does not occur in all patients.<sup>79,80</sup>

DMPA causes reductions in bone mineral density (BMD),<sup>81–83</sup> and in 2004 the US Food and Drug Administration (FDA) issued a black-box warning about the risk of decreased BMD among DMPA users.<sup>84</sup> Subsequent publications document a substantial recovery of BMD after the patient discontinues DMPA,<sup>85–87</sup> and ACOG, recognizing the risk of unwanted pregnancy if women's contraceptive options are limited, does not advise limiting DMPA use to 2 years (in contrast to earlier concerns<sup>88</sup>) or routinely monitoring bone density after that time frame.<sup>89</sup> Nonetheless, it remains



important to consider other risk factors for osteoporosis and to tailor counseling and recommendations to each patient. All patients should be counseled about measures that promote skeletal health, such as daily intake of 1300 mg of calcium and 600 IU of vitamin D and regular weight-bearing exercise.<sup>90</sup>

### Combined Oral Contraceptive Pills

COCs are the most popular method of hormonal contraception for adolescents. COCs all contain a progestin and an estrogen. In almost every pill, the estrogen component is ethinyl estradiol in amounts varying from 10 to 50 µg. Many adolescent medicine experts begin with a COC containing 30 to 35 µg of ethinyl estradiol and a progestin such as levonorgestrel or norgestimate. However, any “low-dose” pill (ie, containing ethinyl estradiol 35 µg or less) can be used. Although inspection of the external genitalia and a vaginal swab or urine screen for STIs are recommended practices in the care of sexually active patients,<sup>91</sup> no gynecologic examination is needed to determine eligibility for COC use. Like other combined methods including the contraceptive vaginal ring and transdermal patch, COCs can be started on the same day as the visit (“quick start”) in healthy, nonpregnant adolescents. Patients should be counseled that a backup method (ie, condoms or abstinence) should be used for at least the first 7 days for contraceptive efficacy and that a condom should be used at all times for protection against STIs. The CDC recommends prescribing up to 1 year of COCs at a time.<sup>52</sup> Additionally, a routine follow-up visit 1 to 3 months after initiating COCs is useful for addressing adverse effects or adherence issues.

COCs have few contraindications in healthy female adolescents. They should not be prescribed for patients with severe and uncontrolled hypertension (systolic pressure  $\geq 160$  mm Hg or

diastolic pressure  $\geq 100$  mm Hg), ongoing hepatic dysfunction, complicated valvular heart disease, migraines with aura or focal neurologic symptoms, thromboembolism or thrombophilia, complications of diabetes (ie, nephropathy, retinopathy, neuropathy, or other vascular disease), and complicated solid organ transplantation.<sup>37</sup> The most serious adverse event associated with COC use is the increased risk of blood clots, which increases from 1 per 10 000 to 3 to 4 per 10 000 woman-years during COC use.<sup>92,93</sup> In comparison, the incidence of venous thromboembolism associated with pregnancy and postpartum is 10 to 20 per 10 000 woman-years, of which 1% to 2% are fatal.<sup>94,95</sup> Although smoking should be discouraged, it is not a contraindication to COC use in teenagers and adults younger than 35 years old.<sup>37</sup>

Patients should be informed that common transient adverse effects of COCs include irregular bleeding, headache, and nausea. Recommendations for managing adverse effects have been published elsewhere<sup>96</sup> or can be found online (<http://www.managingcontraception.com/qa/index.php> or [http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6205a1.htm?s\\_cid=rr6205a1\\_w](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6205a1.htm?s_cid=rr6205a1_w)).<sup>52</sup> Drug interactions should also be avoided. With medications that decrease COC effectiveness (eg, anti-convulsants and antiretroviral drugs), patients may benefit from choosing an alternative method or dosing<sup>97</sup> (see the accompanying technical report for additional details). Most broad-spectrum antibiotics (rifampin is an exception) do not affect the contraceptive effectiveness of COCs.<sup>37</sup>

Typical use failure rates are 9% in adults and may be higher in adolescents.<sup>32,98</sup> Counseling should include strategies to promote daily adherence, such as cell phone alarms and support from a family member or partner. Patients should be instructed

on what to do if pills are missed. A missed pill should be taken as soon as it is remembered. If more than 1 pill in a row is missed, only the most recently missed pill should be taken as soon as possible, and the remaining pills should be taken at the usual time. Patients should be reminded that 7 consecutive hormone pills are needed to prevent ovulation. Additional instructions can be accessed online ([http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6205a1.htm?s\\_cid=rr6205a1\\_w#Fig2](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6205a1.htm?s_cid=rr6205a1_w#Fig2)).<sup>52</sup> EC is indicated if 2 or more pills are missed in the first week of the cycle.<sup>99,100</sup> EC should also be considered if 1 or more pills were missed earlier in the same cycle as a missed pill or late in the previous cycle (see online instructions provided earlier for details).

Many patients may benefit from decreasing or eliminating the hormone-free (placebo) interval. Extended or continuous cycles may be useful for treating medical conditions such as anemia, acne, severe dysmenorrhea, endometriosis, dysfunctional or heavy menstrual bleeding, Von Willebrand disease, and other bleeding diatheses and for adolescents who prefer amenorrhea.<sup>101</sup> These regimens may also be useful for conditions that can be exacerbated cyclically, such as migraine (without aura), epilepsy, irritable bowel syndrome, inflammatory bowel disease, and some psychiatric and behavioral symptoms<sup>102</sup>; the most common adverse effect of extended or continuous cycles is unscheduled bleeding. Patients may be reassured to know that observational data indicate that COC use does not increase the risk of infertility or breast cancer<sup>103</sup> and that use of COCs for more than 4 years provides significant protection against endometrial and ovarian cancers.<sup>104</sup>

### Contraceptive Vaginal Ring

The vaginal ring (NuvaRing; Merck, Whitehouse Station, NJ) releases a combination

of estrogen and progestin and thus has the same eligibility criteria for use as COCs. As with COCs, a same-day start (“quick start”) can also be used with the vaginal ring. The ring is inserted in the vagina and stays in place for 3 weeks, with removal for 1 week to induce withdrawal bleeding, followed by insertion of a new ring. Patients should be instructed to insert a new ring after 7 days even if bleeding has not ceased.

The ring has comparable efficacy, risks, and benefits as other combined hormonal methods but provides the simplest regimen.<sup>32,105,106</sup> Adverse effects are also similar, with the additional vaginal symptoms of discharge, discomfort, and problems related to the device (eg, expulsion).<sup>107</sup> The ring is an excellent method for extended use because, although labeled for 28 days of use, the rings contain sufficient medication to be used for up to 35 days<sup>108</sup> and thus can be replaced once every calendar month. Sexually active patients may be reassured to know that most men were not bothered by its presence, if it was noted at all.<sup>109,110</sup>

### Transdermal Contraceptive Patch

The combination hormone (estrogen and progestin) transdermal contraceptive patch (Ortho Evra; Ortho-McNeil Pharmaceutical, Raritan, NJ) is placed on the abdomen, upper torso, upper outer arm, or buttocks using 1 patch for each of 3 weeks in a row, followed by 1 week off the patch, during which a withdrawal bleed usually occurs. Typical use failure rates are similar to those of COCs at 9%.<sup>32</sup> The FDA has identified increased estrogen exposure (1.6 times higher than with a low-dose COC<sup>111</sup>) and a potential increased risk of venous thromboembolism with the patch<sup>112,113</sup> (see accompanying technical report for more complete discussion).

The patch has comparable efficacy, benefits, eligibility criteria for use, and drug interactions as COCs; side effects are similar to those of other combined methods, with the addition of dislodged patches and skin effects, such as hyperpigmentation,<sup>114,115</sup> contact dermatitis, and other irritation.<sup>116</sup> The risk of pregnancy with correct (“perfect”) use of the patch is slightly higher for women who weigh more than 198 pounds than for women who weigh less (0.9% vs 0.3% in first 12 months of use).<sup>117,118</sup>

### Progestin-Only Pills

Progestin-only pills (also known as “mini-pills”) work primarily by thickening cervical mucus, not by inhibiting ovulation. Because very stringent adherence is necessary, their failure rate can be significantly higher than those of other combined hormonal and progestin-only methods (IUDs and contraceptive implants and injections). However, they provide an additional option for patients who have safety concerns about estrogen use (see accompanying technical report for additional details).<sup>37</sup>

### Male Condoms

The male condom is the most common contraceptive method used by adolescents, with up to 52% of female and 75% of male adolescents reporting condom use at last intercourse.<sup>1</sup> Advantages include male involvement in the responsibility for contraception, easy accessibility by minors without a prescription, and low cost. Latex condoms also reduce STI transmission, with consistent evidence for the reduction of gonorrhea, chlamydia, trichomoniasis,<sup>119–123</sup> and hepatitis B and HIV transmission<sup>124</sup> and emerging evidence for the reduction of herpes simplex virus,<sup>125,126</sup> human papillomavirus,<sup>127,128</sup> and syphilis transmission.<sup>129</sup> However, condom use requires com-

mitment at every sex act, tends to drop off over time, and is influenced by individual, relationship, and broader social factors.<sup>130–133</sup> Although the perfect use failure rate of condoms is 2%, the typical use failure rate is 18% for all users and can be higher among adolescents.<sup>32</sup> The high typical use failure rate, coupled with the condom’s high STI protection, has led to the recommendation for dual contraception: condoms plus a highly effective hormonal or other long-acting method. Instructions for condom use can be found in the accompanying technical report, and additional details are provided in the AAP policy statement on condoms.<sup>133</sup>

### Emergency Contraception

In the United States, EC is available as oral levonorgestrel; an oral progesterone receptor modulator, ulipristal acetate; high-dose combined estrogen–progestin oral contraceptive pills (the Yuzpe regimen); and placement of a copper IUD. Levonorgestrel EC is preferred to the Yuzpe regimen because of the superior adverse effect profile and effectiveness, which is up to 85%.<sup>44,134</sup> Ulipristal acetate may have greater effectiveness than oral levonorgestrel at the end of the 5-day window of use, and its remaining effectiveness and adverse effect profile are similar to those of levonorgestrel.<sup>135,136</sup> In addition, on the basis of recent data about lower efficacy of levonorgestrel EC, ulipristal may be more effective in people who weigh more than 165 pounds.<sup>137,138</sup> Placement of a copper-bearing IUD is less commonly used for EC in adolescents but is the most effective EC method, with a failure rate of less than 1%.<sup>139</sup>

The recommended dosage of levonorgestrel is a single 1.5-mg dose.<sup>134,140</sup> It is available either as 2 pills (0.75 mg each) or as 1 pill (Plan B One-Step; Teva Pharmaceuticals, Petah Tikva, Israel). Levonorgestrel-based EC delays or inhibits ovulation and does not

appear to be effective once ovulation has occurred. If used inadvertently during early pregnancy, it is not teratogenic, only ineffective.<sup>141</sup> Thus, a pregnancy test is not mandatory before levonorgestrel EC is prescribed.<sup>44</sup>

Plan B One-Step is approved by the FDA as a nonprescription product for all women of childbearing potential.<sup>142</sup> Generic versions are approved as a nonprescription product for women 17 years of age and older; however, proof of age is not required to purchase them. Providing EC in advance increases the likelihood of use when it is needed without increasing sexual or contraceptive risk-taking behavior.<sup>143,144</sup> Therefore, EC should be prescribed or recommended in advance for use for up to 5 days after an event of unprotected intercourse.<sup>44</sup> Additional details on EC mechanisms and use can be found in the AAP policy statement on emergency contraception<sup>44</sup> and the accompanying technical report.

### Withdrawal

Withdrawal, or coitus interruptus, is a method in which the male partner attempts to pull out his penis before ejaculation. Because 57% of female adolescents report using withdrawal,<sup>1</sup> pediatricians should ask about it. However, because of its limited effectiveness (22% failure rate among all users)<sup>32</sup> and lack of STI protection, pediatricians should encourage adolescents to adopt more effective methods.

### Other Methods

The female condom, periodic abstinence (fertility awareness or “the rhythm method”), vaginal spermicides, the cervical cap, and the diaphragm are methods less commonly used by adolescents. Additional descriptions are available in the accompanying technical report.

## SPECIAL POPULATIONS

### Adolescents With Disabilities and Medically Complex Illness

An estimated 16% to 25% of adolescents are identified as having special health care needs, including physical disability, developmental disability, and medically complex illness.<sup>145</sup> The improved survival of adolescents with medically complex illnesses, such as disabilities, chronic disease, HIV, and solid organ transplants, has prompted greater attention to quality-of-life issues. These issues, including adolescent interest in romantic and sexual relationships, are typically addressed by a pediatrician. Sexuality and sexual health care needs in this population are often overlooked, yet data demonstrate that, compared with healthy adolescents, adolescents with chronic illness have similar levels of sexual behaviors and sexual health outcomes (eg, STIs).<sup>146,147</sup> In addition to pregnancy prevention, these adolescents may need menstrual suppression for heavy menstrual bleeding, bleeding disorders, or chemotherapy. Other patients may be using teratogenic medications and need contraception for that reason. Issues that arise include safety concerns with estrogen use, medication interactions, and complications from the underlying disease. The CDC has recently addressed the contraceptive needs of young women with medical conditions by publishing the “US Medical Eligibility Criteria for Contraceptive Use.”<sup>37</sup> Available online, this document summarizes the literature on safety and efficacy of different contraceptive methods by medical condition. Additional details on specific populations (eg, those with disabilities) are summarized in the accompanying technical report.

### Adolescents With Obesity

The sexual health needs and sexual behaviors of adolescents with obesity are substantially similar to those of

their normal-weight peers.<sup>148,149</sup> In addressing contraception, it is important to note that obesity and related endocrine effects can influence the efficacy and adverse effects profiles of contraceptives. For example, a small number of excess pregnancies were found among transdermal contraceptive patch users weighing more than 90 kg (198 lb).<sup>117,118</sup> The World Health Organization and CDC report that data are limited and inconsistent about whether COC effectiveness varies by body weight or BMI.<sup>37,150–152</sup> A common concern of both adolescents and providers is additional weight gain among adolescents with obesity after they start contraception. Data suggest that women with obesity are no more likely to gain weight with COCs, the vaginal ring, IUDs, or implants than normal-weight peers. In contrast, adolescents with obesity who used DMPA were more likely than nonusers with obesity, COC users with obesity, and normal-weight DMPA users to gain weight.<sup>80</sup>

Increasing numbers of adolescents are having bariatric surgery procedures performed, and these patients need highly effective contraception. Post-surgery data reveal an improvement in fertility coupled with the potential for decreased contraceptive effectiveness through malabsorption, vomiting, and diarrhea.<sup>86</sup> Professional consensus statements recommend delaying pregnancy for at least 12 months after the procedure.<sup>153</sup> All contraceptive methods are safe for women with a history of bariatric surgery, with the exception of oral contraceptives for women who have undergone malabsorptive procedures.<sup>37</sup> There is increasing experience and success with the levonorgestrel IUD placed at the time of surgery.<sup>154</sup>

### ADHERENCE AND FOLLOW-UP

Frequent follow-up is important to maximize adherence for all methods of contraception and to promote and

reinforce healthy decision-making. Adolescents count on trusted health professionals, such as pediatricians, for support and problem solving around continuation and adherence. Regularly scheduled contraceptive follow-up visits should address use, adherence, adverse effects, and complications. Pediatricians can use motivational interviewing approaches to increase effective and consistent contraceptive use, including engaging parental support for contraceptive adherence, when possible. Follow-up visits should additionally include reassessment of relationships, sexual behaviors, contraceptive needs, STI surveillance and prevention, and other sexual health prevention measures, such as human papillomavirus immunization.

## RECOMMENDATIONS

1. Pediatricians should counsel about and ensure access to a broad range of contraceptive services for their adolescent patients. This includes educating patients about all contraceptive methods that are safe and appropriate for them and describing the most effective methods first.
2. Pediatricians should be able to educate adolescent patients about LARC methods, including the progestin implant and IUDs. Given the efficacy, safety, and ease of use, LARC methods should be considered first-line contraceptive choices for adolescents. Some pediatricians may choose to acquire the skills to provide these methods to adolescents. Those who do not should identify health care providers in their communities to whom patients can be referred.
3. Despite increased attention to adverse effects, DMPA and the contraceptive patch are highly effective methods of contraception that are much safer than pregnancy. Pediatricians should continue to make them available to their patients.
4. Pediatricians should allow the adolescent to consent to contraceptive care and to control the disclosure of this information within the limits of state and federal laws. There are a number of supports for protecting minor consent and confidentiality, including state law, federal statutes, and federal case law. Pediatricians will need to be familiar with national best practice recommendations for confidential care and with the relevant minor consent laws in their states.
5. Pediatricians should be aware that it is appropriate to prescribe contraceptives or refer for IUD placement without first conducting a pelvic examination. Screenings for STIs, especially chlamydia, can be performed without a pelvic examination and should not be delayed.
6. Pediatricians should encourage the consistent and correct use of condoms with every act of sexual intercourse.
7. Pediatricians should have a working knowledge of the different combined hormonal methods and regimens, because these provide excellent cycle control both for contraception and medical management of common conditions, such as acne, dysmenorrhea, and heavy menstrual bleeding.
8. Pediatricians should remember that adolescents with chronic illness and disabilities have similar sexual health and contraceptive needs to healthy adolescents while recognizing that medical illness may complicate contraceptive choices.
9. Pediatricians should regularly update their adolescent patients' sexual histories and provide a confidential and nonjudgmental setting in which to address needs for contraception, STI screening, and sexual risk reduction counseling for patients who choose not to be abstinent.
10. Pediatricians should allow sufficient time with their adolescent patients to address contraceptive needs using a developmentally appropriate, patient-centered approach, such as motivational interviewing. If necessary, arrangements should be made for a separate visit for contraceptive follow-up to increase adherence and monitor for adverse effects and complications.
11. Pediatricians can complement the skills and resources of the pediatric office by being aware of state or federally subsidized insurance programs and clinics that provide confidential and free or low-cost reproductive health care services and supplies, including contraception.

### LEAD AUTHORS

Mary A. Ott, MD, MA, FAAP  
Gina S. Sucato, MD, MPH, FAAP

### COMMITTEE ON ADOLESCENCE, 2013–2014

Paula K. Braverman, MD, Chairperson  
William P. Adelman, MD, FAAP  
Elizabeth M. Alderman, MD, FAAP, FSHAM  
Cora C. Breuner, MD, MPH, FAAP  
David A. Levine, MD, FAAP  
Arik V. Marcell, MD, FAAP  
Rebecca F. O'Brien, MD, FAAP

### PAST COMMITTEE MEMBER

Pamela J. Murray, MD, MPH, FAAP

### LIAISONS

Loretta E. Gavin, PhD, MPH – *Centers for Disease Control and Prevention*  
Margo Lane, MD, FRCPC – *Canadian Pediatric Society*  
Rachel J. Miller, MD – *American College of Obstetricians and Gynecologists*  
Benjamin Shain, MD, PhD – *American Academy of Child and Adolescent Psychiatry*

### STAFF

Karen S. Smith  
James D. Baumberger, MPP



## REFERENCES

- Martinez G, Copen CE, Abma JC. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2006–2010 national survey of family growth. *Vital Health Stat* 23. 2011; (31):1–35
- Kost K, Henshaw S, Carlin L. *US Teenage Pregnancies, Births and Abortions: National and State Trends and Trends by Race and Ethnicity*. New York, NY: Guttmacher Institute; 2010
- Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. *Contraception*. 2011;84(5): 478–485
- Ott MA, Rosenberger JG, McBride KR, Woodcox SG. How do adolescents view health? Implications for state health policy. *J Adolesc Health*. 2011;48(4):398–403
- Jones RK, Biddlecom AE. The more things change...: the relative importance of the internet as a source of contraceptive information for teens. *Sex Res Soc Policy*. 2011;8(1):27–37
- Institute of Medicine, Committee on Preventive Services for Women. *Clinical Preventive Services for Women: Closing the Gaps*. Washington, DC: National Academies Press; 2011
- Health Resources and Services Administration. *Women's Preventive Services: Required Health Plan Coverage Guidelines*. Rockville, MD: Health Resources and Services Administration; 2012
- The Patient Protection and Affordable Care Act. Pub L No. 111-148 (2010). Available at: [www.doi.gov/ebsa/healthreform/](http://www.doi.gov/ebsa/healthreform/). Accessed January 13, 2014
- Ford C, English A, Sigman G. Confidential Health Care for Adolescents: position paper for the society for adolescent medicine. *J Adolesc Health*. 2004;35(2):160–167. Available at: [www.adolescenthealth.org/SAHM\\_Main/media/Advocacy/Positions/Aug-04-Confidential\\_Health\\_Care\\_for\\_Adolescents.pdf](http://www.adolescenthealth.org/SAHM_Main/media/Advocacy/Positions/Aug-04-Confidential_Health_Care_for_Adolescents.pdf). Accessed June 22, 2014
- American College of Obstetricians and Gynecologists. *Guidelines for Adolescent Health Care*. Washington, DC: American College of Obstetricians and Gynecologists; 2011
- American Academy of Pediatrics, Committee on Adolescence. Policy statement: achieving quality health services for adolescents. *Pediatrics*. 2008;121(6):1263–1270. Available at: <http://pediatrics.aappublications.org/content/121/6/1263.full.pdf+html>. Accessed June 22, 2014
- Center for Adolescent Health and the Law. *State Minor Consent Laws: A Summary*. 3rd ed. Chapel Hill, NC: Center for Adolescent Health and the Law; 2010
- Guttmacher Institute. An overview of minors' consent law. State policies in brief as of June 1, 2014. Available at: [www.guttmacher.org/statecenter/spibs/spib\\_MACS.pdf](http://www.guttmacher.org/statecenter/spibs/spib_MACS.pdf). Accessed June 20, 2014
- English A, Ford CA. The HIPAA privacy rule and adolescents: legal questions and clinical challenges. *Perspect Sex Reprod Health*. 2004;36(2):80–86
- Spooner SA; Council on Clinical Information Technology, American Academy of Pediatrics. Special requirements of electronic health record systems in pediatrics. *Pediatrics*. 2007;119(3):631–637 <http://pediatrics.aappublications.org/content/119/3/631.full.pdf+html>. Accessed June 22, 2014
- Council on Clinical Information Technology. Health information technology and the medical home. *Pediatrics*. 2011;127(5):978–982. Available at: <http://pediatrics.aappublications.org/content/127/5/978.full?sid=f3089a2a-b98c-4046-99c3-4e5386ef6e20>. Accessed June 22, 2014
- Reddy DM, Fleming R, Swain C. Effect of mandatory parental notification on adolescent girls' use of sexual health care services. *JAMA*. 2002;288(6):710–714
- Zabin LS, Stark HA, Emerson MR. Reasons for delay in contraceptive clinic utilization. Adolescent clinic and nonclinic populations compared. *J Adolesc Health*. 1991;12(3): 225–232
- Guldi M. Fertility effects of abortion and birth control pill access for minors. *Demography*. 2008;45(4):817–827
- Zavodny M. Fertility and parental consent for minors to receive contraceptives. *Am J Public Health*. 2004;94(8):1347–1351
- Lehrer JA, Pantell R, Tebb K, Shafer MA. Forgone health care among U.S. adolescents: associations between risk characteristics and confidentiality concern. *J Adolesc Health*. 2007;40(3):218–226
- Dempsey AF, Singer DD, Clark SJ, Davis MM. Adolescent preventive health care: what do parents want? *J Pediatr*. 2009;155(5):689.e1–694.e1
- Jones RK, Purcell A, Singh S, Finer LB. Adolescents' reports of parental knowledge of adolescents' use of sexual health services and their reactions to mandated parental notification for prescription contraception. *JAMA*. 2005;293(3):340–348
- Hagan JF, Shaw JS, Duncan PM, eds. *Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents*. Elk Grove Village, IL: American Academy of Pediatrics; 2008. Available at: [http://brightfutures.aap.org/pdfs/Guidelines\\_PDF/18-Adolescence.pdf](http://brightfutures.aap.org/pdfs/Guidelines_PDF/18-Adolescence.pdf). Accessed June 22, 2014
- Centers for Disease Control and Prevention. *A Guide to Taking a Sexual History*. Atlanta, GA: Centers for Disease Control and Prevention; 2005. Available at: [www.cdc.gov/std/treatment/SexualHistory.pdf](http://www.cdc.gov/std/treatment/SexualHistory.pdf). Accessed June 22, 2014
- Blum RW. Healthy youth development as a model for youth health promotion. A review. *J Adolesc Health*. 1998;22(5):368–375
- Ott MA, Lobbett RL, Gold MA. Counseling adolescents about abstinence in the office setting. *J Pediatr Adolesc Gynecol*. 2007;20(1):39–44
- American Academy of Pediatrics, Committee on Adolescence. Technical report: contraception for adolescents. *Pediatrics*. 2014; (in press)
- Brückner H, Bearman P. After the promise: the STD consequences of adolescent virginity pledges. *J Adolesc Health*. 2005; 36(4):271–278
- Pinkerton SD. A relative risk-based, disease-specific definition of sexual abstinence failure rates. *Health Educ Behav*. 2001; 28(1):10–20
- Committee on Adolescence. Office-based care for lesbian, gay, bisexual, transgender, and questioning youth. *Pediatrics*. 2013;132(1):198–203. Available at: <http://pediatrics.aappublications.org/content/132/1/198.full.pdf>. Accessed June 22, 2014
- Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Kowal D, Policar MS. *Contraceptive Technology*. 20th rev ed. Valley Stream, NY: Ardent Media; 2011
- Graesslin O, Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. *Eur J Contracept Reprod Health Care*. 2008;13 (suppl 1):4–12
- Lakha F, Glasier AF. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting. *Contraception*. 2006;74(4):287–289
- Harvey C, Seib C, Lucke J. Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland, Australia. *Contraception*. 2009;80(6):527–532
- Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists. Committee opinion no. 539: adolescents and long-acting reversible

- contraception: implants and intrauterine devices. *Obstet Gynecol.* 2012;120(4):983–988
37. Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use, 2010. *MMWR Recomm Rep.* 2010;59(RR-4):1–6. Available at: [www.cdc.gov/mmwr/preview/mmwrhtml/rr5904a1.htm?s\\_cid=rr5904a1\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5904a1.htm?s_cid=rr5904a1_e). Accessed June 22, 2014
  38. Gurtcheff SE, Turok DK, Stoddard G, Murphy PA, Gibson M, Jones KP. Lactogenesis after early postpartum use of the contraceptive implant: a randomized controlled trial. *Obstet Gynecol.* 2011;117(5):1114–1121
  39. Kapp N, Curtis K, Nanda K. Progestogen-only contraceptive use among breastfeeding women: a systematic review. *Contraception.* 2010;82(1):17–37
  40. Bayer HealthCare Pharmaceuticals. Skyla package insert. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2013. Available at: [http://labeling.bayerhealthcare.com/html/products/pi/Skyla\\_PI.pdf](http://labeling.bayerhealthcare.com/html/products/pi/Skyla_PI.pdf). Accessed January 13, 2014
  41. Bayer HealthCare Pharmaceuticals. Mirena package insert. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2013. Available at: [http://labeling.bayerhealthcare.com/html/products/pi/Mirena\\_PI.pdf](http://labeling.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf). Accessed January 13, 2014
  42. Teva Women's Health Inc/Teva Pharmaceuticals. Paragard package insert. Sellersville, PA: Teva Woman's Health Inc/Teva Pharmaceuticals; 2011. Available at: <http://paragard.com/Pdf/ParaGard-PI.pdf>. Accessed June 22, 2014
  43. Trussell J. Update on and correction to the cost-effectiveness of contraceptives in the United States. *Contraception.* 2012;85(6):611
  44. Committee on Adolescence. Emergency contraception. *Pediatrics.* 2012;130(6):1174–1182
  45. Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzmán-Rodríguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. *N Engl J Med.* 2001;345(8):561–567
  46. Hov GG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility: follow-up after participation in a randomized clinical trial. *Contraception.* 2007;75(2):88–92
  47. Penney G, Brechin S, de Souza A, et al; Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFRHC guidance (January 2004). The copper intrauterine device as long-term contraception. *J Fam Plann Reprod Health Care.* 2004;30(1):29–41, quiz 42
  48. Mohilajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. *Contraception.* 2006;73(2):145–153
  49. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. *Lancet.* 1992;339(8796):785–788
  50. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 121: Long-acting reversible contraception: implants and intrauterine devices. *Obstet Gynecol.* 2011;118(1):184–196
  51. Grimes DA. Intrauterine device and upper-genital-tract infection. *Lancet.* 2000;356(9234):1013–1019
  52. Centers for Disease Control and Prevention. US selected practice recommendations for contraceptive use, 2013: adapted from the World Health Organization Selected Practice Recommendations for Contraceptive Use, 2nd Edition. *MMWR Recomm Rep.* 2013;62(RR-5):1–60
  53. Grimes DA, Lopez LM, Schulz KF, Van Vliet HA, Stanwood NL. Immediate post-partum insertion of intrauterine devices. *Cochrane Database Syst Rev.* 2010; (5):CD003036
  54. Kapp N, Curtis KM. Intrauterine device insertion during the postpartum period: a systematic review. *Contraception.* 2009;80(4):327–336
  55. American College of Obstetricians and Gynecologists. Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. ACOG committee opinion no. 450. *Obstet Gynecol.* 2009;114(6):1434–1438
  56. Chen BA, Reeves MF, Hayes JL, Hohmann HL, Perriera LK, Creinin MD. Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery: a randomized controlled trial. *Obstet Gynecol.* 2010;116(5):1079–1087
  57. Ogburn JA, Espey E, Stonehocker J. Barriers to intrauterine device insertion in postpartum women. *Contraception.* 2005;72(6):426–429
  58. Deans EI, Grimes DA. Intrauterine devices for adolescents: a systematic review. *Contraception.* 2009;79(6):418–423
  59. Thonneau P, Almont T, de La Rochebrochard E, Maria B. Risk factors for IUD failure: results of a large multicentre case-control study. *Hum Reprod.* 2006;21(10):2612–2616
  60. Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. *Contraception.* 2004;69(5):407–412
  61. Bayer LL, Jensen JT, Li H, Nichols MD, Bednarek PH. Adolescent experience with intrauterine device insertion and use: a retrospective cohort study. *Contraception.* 2012;86(5):443–451
  62. Alton TM, Brock GN, Yang D, Wilking DA, Hertweck SP, Loveless MB. Retrospective review of intrauterine device in adolescent and young women. *J Pediatr Adolesc Gynecol.* 2012;25(3):195–200
  63. Godfrey EM, Memmel LM, Neustadt A, et al. Intrauterine contraception for adolescents aged 14–18 years: a multicenter randomized pilot study of levonorgestrel-releasing intrauterine system compared to the Copper T 380A. *Contraception.* 2010;81(2):123–127
  64. Paterson H, Ashton J, Harrison-Woolrych M. A nationwide cohort study of the use of the levonorgestrel intrauterine device in New Zealand adolescents. *Contraception.* 2009;79(6):433–438
  65. Pillai M, O'Brien K, Hill E. The levonorgestrel intrauterine system (Mirena) for the treatment of menstrual problems in adolescents with medical disorders, or physical or learning disabilities. *BJOG.* 2010;117(2):216–221
  66. Toma A, Jamieson MA. Revisiting the intrauterine contraceptive device in adolescents. *J Pediatr Adolesc Gynecol.* 2006;19(4):291–296
  67. Lara-Torre E, Spotswood L, Correia N, Weiss PM. Intrauterine contraception in adolescents and young women: a descriptive study of use, side effects, and compliance. *J Pediatr Adolesc Gynecol.* 2011;24(1):39–41
  68. Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. *Contraception.* 2009;80(1):7–17
  69. Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. *J Reprod Med.* 1996;41(5 suppl):419–427
  70. Herzog AG. Progesterone therapy in women with epilepsy: a 3-year follow-up. *Neurology.* 1999;52(9):1917–1918
  71. de Abood M, de Castillo Z, Guerrero F, Espino M, Austin KL. Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. *Contraception.* 1997;56(5):313–316
  72. Manchikanti A, Grimes DA, Lopez LM, Schulz KF. Steroid hormones for contraception in women with sickle cell disease. *Cochrane Database Syst Rev.* 2007; (2):CD006261

73. Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. *Contraception*. 2009; 80(2):113–118
74. Arias RD, Jain JK, Brucker C, Ross D, Ray A. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. *Contraception*. 2006;74(3):234–238
75. Hubacher D, Goco N, Gonzalez B, Taylor D. Factors affecting continuation rates of DMPA. *Contraception*. 1999;60(6):345–351
76. Canto De Cetina TE, Canto P, Ordoñez Luna M. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. *Contraception*. 2001;63(3):143–146
77. Bonny AE, Secic M, Cromer B. Early weight gain related to later weight gain in adolescents on depot medroxyprogesterone acetate. *Obstet Gynecol*. 2011;117(4):793–797
78. Le YC, Rahman M, Berenson AB. Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users. *Obstet Gynecol*. 2009;114(2 pt 1):279–284
79. Risser WL, Geffer LR, Barratt MS, Risser JM. Weight change in adolescents who used hormonal contraception. *J Adolesc Health*. 1999;24(6):433–436
80. Bonny AE, Ziegler J, Harvey R, Debanne SM, Secic M, Cromer BA. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. *Arch Pediatr Adolesc Med*. 2006;160(1):40–45
81. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. *J Pediatr*. 1996;129(5):671–676
82. Lara-Torre E, Edwards CP, Perlman S, Hertweck SP. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. *J Pediatr Adolesc Gynecol*. 2004;17(1):17–21
83. Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. *J Adolesc Health*. 2004;35(6):434–441
84. Pfizer. *DepoProvera 150 mg and Depo SubQ Provera 104 package inserts*. Cambridge, MA: Pfizer; 2005
85. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. *Arch Pediatr Adolesc Med*. 2005;159(2):139–144
86. Harel Z, Johnson CC, Gold MA, et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. *Contraception*. 2010;81(4): 281–291
87. Berenson AB, Rahman M, Breitkopf CR, Bi LX. Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. *Obstet Gynecol*. 2008;112(4):788–799
88. US Pharmaceuticals/Pfizer Inc. Letter to health care professionals. November 18, 2004. Available at: [www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM1-66395.pdf](http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM1-66395.pdf). Accessed January 13, 2014
89. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion no. 415: depot medroxyprogesterone acetate and bone effects. *Obstet Gynecol*. 2008;112(3): 727–730
90. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academies Press; 2010. Available at: [www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-calcium-and-vitamin-D.aspx](http://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-calcium-and-vitamin-D.aspx)
91. Braverman PK, Breech L; Committee on Adolescence. American Academy of Pediatrics. Clinical report: gynecologic examination for adolescents in the pediatric office setting. *Pediatrics*. 2010;126(3):583–590. Available at: <http://pediatrics.aappublications.org/content/126/3/583.full.pdf+html>. Accessed June 22, 2014
92. Trenor CC III, Chung RJ, Michelson AD, et al. Hormonal contraception and thrombotic risk: a multidisciplinary approach. *Pediatrics*. 2011;127(2):347–357
93. Vandembroucke JP, Rosing J, Bloemkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. *N Engl J Med*. 2001; 344(20):1527–1535
94. Walker ID. Venous and arterial thrombosis during pregnancy: epidemiology. *Semin Vasc Med*. 2003;3(1):25–32
95. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. *Ann Intern Med*. 2005;143(10):697–706
96. Dickey R. *Managing Contraceptive Pill Patients*. Fort Collins, CO: EMIS Inc Medical Publishers; 2010
97. Gaffield ME, Culwell KR, Lee CR. The use of hormonal contraception among women taking anticonvulsant therapy. *Contraception*. 2011;83(1):16–29
98. Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. *Vital Health Stat* 23. 2010; (29):1–44
99. Faculty of Sexual and Reproductive Healthcare, Royal College of Obstetricians and Gynaecologists. *Faculty of Sexual and Reproductive Healthcare Clinical Guidance: Combined Hormonal Contraception*. London, UK: Faculty of Sexual and Reproductive Healthcare, Royal College of Obstetricians and Gynaecologists; October 2011. Updated August 2012. Available at: [www.fsrh.org/pdfs/CEUGuidanceCombined-HormonalContraception.pdf](http://www.fsrh.org/pdfs/CEUGuidanceCombined-HormonalContraception.pdf). Accessed January 13, 2014
100. Mansour D. Revision of the “missed pill” rules. *J Fam Plann Reprod Health Care*. 2011;37(3):128–131
101. Sucato GS, Gold MA. Extended cycling of oral contraceptive pills for adolescents. *J Pediatr Adolesc Gynecol*. 2002;15(5): 325–327
102. Sucato GS, Gerschultz KL. Extended cycle hormonal contraception in adolescents. *Curr Opin Obstet Gynecol*. 2005;17(5):461–465
103. ACOG Committee on Practice Bulletins–Gynecology. ACOG practice bulletin no. 73: Use of hormonal contraception in women with coexisting medical conditions. *Obstet Gynecol*. 2006;107(6):1453–1472
104. Vessey M, Painter R. Oral contraceptive use and cancer: Findings in a large cohort study, 1968–2004. *Br J Cancer*. 2006;95(3): 385–389
105. Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. *Hum Reprod*. 2001;16(3):469–475
106. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. *Obstet Gynecol*. 2002;100(3):585–593
107. Edwardson J, Jamshidi R. The contraceptive vaginal ring. *Semin Reprod Med*. 2010; 28(2):133–139
108. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. *Clin Pharmacokinet*. 2000;39 (3):233–242
109. Guida M, Di Spiezo Sardo A, Bramante S, et al. Effects of two types of hormonal contraception—oral versus intravaginal—on the sexual life of women and their partners. *Hum Reprod*. 2005;20(4):1100–1106

110. Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. *Obstet Gynecol.* 2004;104(3):555–563
111. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. *Contraception.* 2005;72(3):168–174
112. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. *Obstet Gynecol.* 2007;109(2 pt 1):339–346
113. Dore DD, Norman H, Loughlin J, Seeger JD. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. *Contraception.* 2010;81(5):408–413
114. Harel Z, Riggs S, Vaz R, Flanagan P, Dunn K, Harel D. Adolescents' experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra. *J Pediatr Adolesc Gynecol.* 2005;18(2):85–90
115. Rubinstein ML, Halpern-Felsher BL, Irwin GE Jr. An evaluation of the use of the transdermal contraceptive patch in adolescents. *J Adolesc Health.* 2004;34(5):395–401
116. Stricker T, Sennhauser FH. Allergic contact dermatitis due to transdermal contraception patch. *J Pediatr.* 2006;148(6):845
117. Audet MC, Moreau M, Koltun WD, et al; ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. *JAMA.* 2001;285(18):2347–2354
118. Ziemann M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. *Fertil Steril.* 2002;77(2 Suppl 2):S13–S18
119. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. *Bull World Health Organ.* 2004;82(6):454–461
120. Gallo MF, Steiner MJ, Warner L, et al. Self-reported condom use is associated with reduced risk of chlamydia, gonorrhea, and trichomoniasis. *Sex Transm Dis.* 2007;34(10):829–833
121. Warner L, Macaluso M, Newman D, et al. Condom effectiveness for prevention of *C trachomatis* infection. *Sex Transm Infect.* 2006;82(3):265
122. Paz-Bailey G, Koumans EH, Sternberg M, et al. The effect of correct and consistent condom use on chlamydial and gonococcal infection among urban adolescents. *Arch Pediatr Adolesc Med.* 2005;159(6):536–542
123. Niccolai LM, Rowhani-Rahbar A, Jenkins H, Green S, Dunne DW. Condom effectiveness for prevention of *Chlamydia trachomatis* infection. *Sex Transm Infect.* 2005;81(4):323–325
124. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. *Cochrane Database Syst Rev.* 2002; (1):CD003255
125. Martin ET, Krantz E, Gottlieb SL, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. *Arch Intern Med.* 2009;169(13):1233–1240
126. Stanaway JD, Wald A, Martin ET, Gottlieb SL, Magaret AS. Case-crossover analysis of condom use and herpes simplex virus type 2 acquisition. *Sex Transm Dis.* 2012;39(5):388–393
127. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. *N Engl J Med.* 2006;354(25):2645–2654
128. Shew ML, Fortenberry JD, Tu W, et al. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. *Arch Pediatr Adolesc Med.* 2006;160(2):151–156
129. Koss CA, Dunne EF, Warner L. A systematic review of epidemiologic studies assessing condom use and risk of syphilis. *Sex Transm Dis.* 2009;36(7):401–405
130. Matson PA, Adler NE, Millstein SG, Tschann JM, Ellen JM. Developmental changes in condom use among urban adolescent females: influence of partner context. *J Adolesc Health.* 2011;48(4):386–390
131. Bearinger LH, Sieving RE, Duke NN, McMorris BJ, Stoddard S, Pettingell SL. Adolescent condom use consistency over time: global versus partner-specific measures. *Nurs Res.* 2011;60(3 suppl):S68–S78
132. Kenyon DB, Sieving RE, Jerstad SJ, Pettingell SL, Skay CL. Individual, interpersonal, and relationship factors predicting hormonal and condom use consistency among adolescent girls. *J Pediatr Health Care.* 2010;24(4):241–249
133. American Academy of Pediatrics, Committee on Adolescence. Policy statement: condom use by adolescents. *Pediatrics.* 2013;132(5):973–981
134. Cheng L, Gülmezoglu AM, Piaggio G, Ezcurra E, Van Look PF. Interventions for emergency contraception. *Cochrane Database Syst Rev.* 2008; (2):CD001324
135. Fine P, Mathé H, Ginde S, Cullins V, Morfesis J, Gainer E. Ulipristal acetate taken 48–120 hours after intercourse for emergency contraception. *Obstet Gynecol.* 2010;115(2 Pt 1):257–263
136. Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. *Lancet.* 2010;375(9714):555–562
137. Rockoff JD. FDA reviewing efficacy of Plan B contraception in women over 165 pounds. *The Wall Street Journal.* November 25, 2013. Available at: <http://online.wsj.com/news/articles/SB1000142405270-2304011304579220533719517944>. Accessed January 13, 2014
138. Glasier A, Cameron ST, Bliethe D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. *Contraception.* 2011;84(4):363–367
139. Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. *Hum Reprod.* 2012;27(7):1994–2000
140. von Hertzen H, Piaggio G, Ding J, et al; WHO Research Group on Post-ovulatory Methods of Fertility Regulation. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. *Lancet.* 2002;360(9348):1803–1810
141. Gallo MF, Grimes DA, Schulz KF, Helmerhorst FM. Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials. *Obstet Gynecol.* 2004;103(2):359–373
142. US Food and Drug Administration. FDA approves Plan B One-Step emergency contraceptive for use without a prescription for all women of child-bearing potential. June 20, 2013. Available at: [www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm358082.htm](http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm358082.htm). Accessed January 13, 2014
143. Ellertson C, Ambardekar S, Hedley A, Coyaji K, Trussell J, Blanchard K. Emergency contraception: randomized comparison of advance provision and information only. *Obstet Gynecol.* 2001;98(4):570–575
144. Meyer JL, Gold MA, Haggerty CL. Advance provision of emergency contraception



- among adolescent and young adult women: a systematic review of literature. *J Pediatr Adolesc Gynecol*. 2011;24(1):2–9
145. Bethell CD, Read D, Blumberg SJ, Newacheck PW. What is the prevalence of children with special health care needs? Toward an understanding of variations in findings and methods across three national surveys. *Matern Child Health J*. 2008;12(1):1–14
146. McRee AL, Haydon AA, Halpern CT. Reproductive health of young adults with physical disabilities in the U.S. *Prev Med*. 2010;51(6):502–504
147. Surís JC, Resnick MD, Cassuto N, Blum RW. Sexual behavior of adolescents with chronic disease and disability. *J Adolesc Health*. 1996;19(2):124–131
148. Akers AY, Lynch CP, Gold MA, et al. Exploring the relationship among weight, race, and sexual behaviors among girls. *Pediatrics*. 2009;124(5). Available at: [www.pediatrics.org/cgi/content/full/124/5/e913](http://www.pediatrics.org/cgi/content/full/124/5/e913)
149. Mond J, van den Berg P, Boutelle K, Hannan P, Neumark-Sztainer D. Obesity, body dissatisfaction, and emotional well-being in early and late adolescence: findings from the project EAT study. *J Adolesc Health*. 2011;48(4):373–378
150. Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. *Obstet Gynecol*. 2012;120(1):21–26
151. Hormonal contraceptives for contraception in overweight or obese women. *Obstet Gynecol*. 2010;116(5):1206–1207
152. Brunner Huber LR, Toth JL. Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth. *Am J Epidemiol*. 2007;166(11):1306–1311
153. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 105: bariatric surgery and pregnancy. *Obstet Gynecol*. 2009;113(6):1306–1311
154. Hillman JB, Miller RJ, Inge TH. Menstrual concerns and intrauterine contraception among adolescent bariatric surgery patients. *J Womens Health (Larchmt)*. 2011;20(4):533–538

**Contraception for Adolescents**  
COMMITTEE ON ADOLESCENCE  
*Pediatrics* originally published online September 29, 2014;

**Updated Information & Services**

including high resolution figures, can be found at:  
<http://pediatrics.aappublications.org/content/early/2014/09/24/peds.2014-2299>

**Permissions & Licensing**

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:  
<https://shop.aap.org/licensing-permissions/>

**Reprints**

Information about ordering reprints can be found online:  
<http://classic.pediatrics.aappublications.org/content/reprints>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since . Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2014 by the American Academy of Pediatrics. All rights reserved. Print ISSN: .

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



# PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

## **Contraception for Adolescents** COMMITTEE ON ADOLESCENCE

*Pediatrics* originally published online September 29, 2014;

The online version of this article, along with updated information and services, is  
located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/early/2014/09/24/peds.2014-2299>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since . Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2014 by the American Academy of Pediatrics. All rights reserved. Print ISSN: .

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

